Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Neuroendocrine Tumors
Study Phase
Phase 3
Study Completion Date
January 2015
NCT00569127Uploaded 02-24-2018
Access via NCI by Request
PDS UID: nci-data-371
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Provider Information
Provider Data DescriptionThis dataset will allow users to reproduce toxicity analyses reported in the Journal of Clinical Oncology (Yao et al., JCO, 2017, PMID referenced above), which included adverse events among patients with advanced NETs in the SWOG Phase III trial, S0518 (NCT00569127), receiving bevacizumab + octreotide or interferon alfa-2b + octreotide.
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving octreotide acetate together with recombinant interferon alfa-2b is more effective than giving octreotide acetate together with bevacizumab in treating patients with neuroendocrine tumor.
ConditionsAtypical Carcinoid Tumor
Carcinoid Tumor
Colorectal Neuroendocrine Tumor G1
Gastric Neuroendocrine Tumor G1
Neuroendocrine Neoplasm
Intervention TypeBiological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Octreotide Acetate
Biological: Recombinant Interferon Alfa-2b
Drug(s)Drug: Octreotide Acetate
Total Enrolled427
RandomizationRandomized
Blinding MethodNone (Open Label)
Arms InterventionArm I (octreotide acetate and bevacizumab) - Experimental
Arm II (octreotide acetate and recombinant interferon alfa-2b) - Experimental
Secondary IDNCI-2009-00778
PubMed (PMID)28384065
Collaborator(s)NA
Region(s)United States
Age RangeMinimum Age: N/A
Maximum Age: N/A
Files: NCT00569127-D2
Data DictionaryNCT00569127-D2-Data-Dictionary.pdf
DATANCT00569127-D2-Dataset.csv
OTHERREADME.pdf
Files: NCT00569127-D1
Data DictionaryNCT00569127-D1-Data-Dictionary.pdf
DATANCT00569127-D1-Dataset.csv
OTHERREADME.pdf
© 2021 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use